Phospholipase A2 inhibitors
US4933365A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jan 25, 1989 |
| Grant date | Jun 12, 1990 |
| Priority date | — |
| Expiry date | Jan 25, 2009 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/335
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There is disclosed a method for the treatment of immunoinflammatory conditions, such as allergy, anaphylaxis, asthma and inflammation in mammals which comprises administering to a mammal so afflicated an effective amount of a compound having the formula: ##STR1## wherein R.sup.1 and R.sup.2 are each, independently, hydrogen, hydroxy, lower alkyl, lower alkoxy, haloloweralkyl, haloloweralkyl sulfonyl, halo or nitro; PA1 R.sup.3 is hydrogen, lower alkyl, or aryl of 7-12 carbon atoms; PA1 X is ##STR2## A is --CH.sub.2 --, --O-- or --S--; m is 0-8; PA1 n is 0-7, with the proviso that m+n.ltoreq.8; or a pharmacologically acceptable salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.